Business Trip tells the story of businesses at the frontier of mental health and wellness. Each episode features founders, investors, and researchers in psychedelics, neurotechnology, metabolic psychiatry, digital therapeutics, and more.
…
continue reading
1
Comparing Psychedelic Compounds in Therapy (Live Panel at Battery SF)
1:01:53
1:01:53
Play later
Play later
Lists
Like
Liked
1:01:53
Matias hosted a panel at The Battery SF with renowned psychedelics experts, Nolan Williams, Allison Feduccia, Matt Baggott. Nolan is a Stanford professor currently researching ibogaine among other areas in psychiatry and radiology, and he's a founder of TMS company Magnus Medical. Allison is the founder of Psychedelic Support, a platform providing …
…
continue reading
Matias interviews Lili Brillstein about how to work collaboratively with healthcare payers (the ones that reimburse for medical expenses). Lili is a pioneer in the field, having previously led one of the largest bundled payment initiatives at Horizon Blue Cross Blue Shield. She currently is the founder of her own advisory firm, BCollaborative, wher…
…
continue reading
Greg and Matias interview Ed Boyden about neuroscience frontiers and its applications to mental health. Ed is a pioneer in understanding the fundamental mechanisms of the brain. He runs a lab at MIT for Synthetic Neurobiology and is a professor across the departments of neurotechnology, biological engineering, and cognitive science at MIT’s McGover…
…
continue reading
1
5-MeO-DMT in mental healthcare with Steve Rio
50:25
50:25
Play later
Play later
Lists
Like
Liked
50:25
Greg and Matias interview Steve Rio about 5-MeO-DMT and its potential role in mental healthcare. Steve is a social impact cofounder, transformational coach, and practitioner at the Enfold Institute, one of the most reputable aboveground retreat centers working with 5-MeO-DMT. He shared many insights from his hands-on experience guiding hundreds of …
…
continue reading
1
Tom Insel: Startups, AI, Psychedelics, and SSRIs
57:50
57:50
Play later
Play later
Lists
Like
Liked
57:50
Tom Insel is an entrepreneur and former director of the US National Institute of Mental Health, the lead US agency supporting mental health research with a $2 billion budget. Since his time at the NIMH, Tom has built mental health technology, first at Verily and Mindstrong Health, and more recently founded Vanna Health, an online healthcare provide…
…
continue reading
1
Food as Medicine for Mental Health: Drew Ramsey
46:19
46:19
Play later
Play later
Lists
Like
Liked
46:19
What if your next antidepressant was a clam or spinach? Greg & Matias invite Dr. Drew Ramsey to explore nutritional psychiatry - a field exploring how the food we eat can be as powerful as medication in treating mental illnesses like depression and anxiety. Dr. Drew Ramsey is a psychiatrist, entrepreneur and author focusing on nutritional intervent…
…
continue reading
1
Ketogenic Diet for Brain Health: Jan Baszucki
44:19
44:19
Play later
Play later
Lists
Like
Liked
44:19
Can diet treat mental illness? Greg and Matias interview Jan Baszucki of the Baszucki Group whose son Matt overcame bipolar through the ketogenic diet. Jan has supported studies on ketogenic diets and fasting protocols for conditions like depression, schizophrenia, and bipolar disorder. In this episode we discuss: The powerful personal story behind…
…
continue reading
1
Investing in Neurotech 101: Alex Morgan of Khosla Ventures
54:38
54:38
Play later
Play later
Lists
Like
Liked
54:38
Advancements in neuroscience, AI, and bioengineering are unlocking new possibilities for neurotechnologies. Investors are paying attention. Alex Morgan of Khosla Ventures is an MD, PhD, physicist, and one of the most active investors in neurotech startups. He's backed companies harnessing neuromodulation for varied applications - from sleep (Somnee…
…
continue reading
1
All you need is d̶r̶u̶g̶s̶ energy: Motif Neurotech's Implants for Depression
55:00
55:00
Play later
Play later
Lists
Like
Liked
55:00
Neuromodulation flies in the face of modern psychiatry. It can significantly improve mental health without drugs. It allows us to stimulate or inhibit activity in precise regions of the brain using electricity, magnetism or ultrasound. Motif Neurotech is pioneering minimally invasive implants to precisely deliver neuromodulation for mental health. …
…
continue reading
1
Holy poop! Mental health and the gut (part 2 with Bloom Science)
40:15
40:15
Play later
Play later
Lists
Like
Liked
40:15
In part 2 of a 2-part series, Greg and Matias explore microbial therapeutics for mental health with Dr. Christopher Reyes, biophysist, serial enterepreneur, and founder of Bloom Science. Dr. Reyes' research on leveraging microbes to treat neurological conditions began at UC San Francisco. He is now translating his microbiome research into startups …
…
continue reading
1
Holy poop! Mental health and the gut (part 1 with Holobiome)
48:48
48:48
Play later
Play later
Lists
Like
Liked
48:48
Business Trip launched in 2020 as a podcast focused on psychedelics. As Matias and Greg started to dive deeper into the complexities of mental health, they met more and more entrepreneurs and scientists creating novel treatments across many areas of mental health, including the gut microbiome. Dr. Phil Strandwitz pulls back the curtain on the gut-b…
…
continue reading
1
Ketamine for OCD: Carolyn Rodriguez (Stanford pt 3)
38:28
38:28
Play later
Play later
Lists
Like
Liked
38:28
Stanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body. This is part 3 of a 3-part series, where we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We conclude the…
…
continue reading
1
Are psychedelics effective under anesthesia?: Boris Heifets (Stanford pt 2)
37:28
37:28
Play later
Play later
Lists
Like
Liked
37:28
Stanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body. This is part 2 of a 3-part series, where we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We continue wit…
…
continue reading
1
The Startup Landscape for Expanding Consciousness
1:21:12
1:21:12
Play later
Play later
Lists
Like
Liked
1:21:12
Psychedelics have long been known to induce altered states of consciousness. But there are many other techniques that can also expand our awareness - from meditation and breathwork to exploring dreams, prayer, light and sound. In this episode, Greg speaks with Scott Britton about the emerging startup landscape around tools for expanding consciousne…
…
continue reading
1
Stanford Psychedelic Overview: Robert Malenka (Stanford pt 1)
51:18
51:18
Play later
Play later
Lists
Like
Liked
51:18
Stanford University is one of the leading universities in psychedelic science, focusing on understanding how psychedelics work in the body. In this 3-part series, we will explore groundbreaking discoveries via leading Stanford researchers who are revealing the significance of psychedelic science in modern research. We start the series with Robert M…
…
continue reading
Psychedelic Science 2023, Learning Man, MAPS Burn...whatever you want to call it...was a magical conference organized by MAPS. 12k people made the pilgrimage to Denver to discuss psychedelic science, culture, business, art, spirituality, and more. Rick Doblin called this the "Psychedelic 20's" and this event felt like a watershed moment. Luckily, G…
…
continue reading
1
What VCs Look for in Psychedelic Companies
41:57
41:57
Play later
Play later
Lists
Like
Liked
41:57
What does it take for a traditional VC to fund a psychedelic company? In our latest episode, Matias takes us behind the scenes of a panel discussion at the Psychedelic Therapeutics & Drug Development Conference in San Francisco, CA. Matias talks with VCs at firms with $100M+ fund sizes: Anne Dwane, a partner at Village Global, Amanda Way, principal…
…
continue reading
1
Developing Non-Hallucinogenic Psychedelics: Bryan Roth
49:55
49:55
Play later
Play later
Lists
Like
Liked
49:55
In our latest episode, Greg and Matias engage in an insightful discussion with Dr. Bryan Roth, the Michael Hooker Distinguished Professor of Pharmacology at the University of North Carolina Chapel Hill School of Medicine, and the founder of the Roth Lab. Dr. Roth’s lab is on the cutting edge of researching the interaction between brain cell recepto…
…
continue reading
In this week's episode, Greg and Matias take a moment to reflect on the opportunities and challenges they have faced while building the PsyMed Ventures syndicate and venture capital fund since starting the Business Trip podcast in 2020. Their ultimate goal is to support founders who are building ethical businesses in frontier mental health technolo…
…
continue reading
1
The 2023 Psychedelic Industry Landscape with Psychedelic Alpha
49:51
49:51
Play later
Play later
Lists
Like
Liked
49:51
In this week’s episode, Greg and Matias chat with Josh Hardman, the founder of Psychedelic Alpha. Josh is a leading writer and founder at Psychedelic Alpha, an online resource, newsletter, and community covering the intersection of psychedelics and business. He regularly collaborates and writes with experts in the psychedelic field including entrep…
…
continue reading
1
The State of Psychedelics (Part 2): Dr. Rachel Yehuda and Zach Haigney (live recording at Soho House)
53:54
53:54
Play later
Play later
Lists
Like
Liked
53:54
In this week’s special episode, Matias chats with Dr. Rachel Yehuda and Zach Haigney at Soho House in New York City. This is part 2 of a moderated panel recorded in front of a live audience, with part 1 released in June 2022. Dr. Yehuda has spent the last 30 years doing research on PTSD and trauma and is leading the MDMA-assisted therapy research a…
…
continue reading
This episode shares the story of Tactogen, a drug development company making new chemical entities inspired by MDMA. Co-founder Matt Baggott has been fascinated by MDMA and has studied it for 30 years. And while he believes that MDMA can be effective as a therapeutic, his company is developing an MDMA analogue that is designed to be gentler and saf…
…
continue reading
1
Transcranial magnetic stimulation (TMS) paired with ketamine: inside a clinic offering a frontier treatment
50:05
50:05
Play later
Play later
Lists
Like
Liked
50:05
In this new episode of Business Trip, we interview one of the first clinics to offer a protocol that includes TMS (transcranial magnetic stimulation) and ketamine infusion. TMS is a non-invasive procedure that sends electric currents to specific regions in the brain, including areas linked to depression. It's FDA approved and has been gaining adopt…
…
continue reading
1
Perspectives from Christian Angermayer, investor and founder in psychedelics
42:34
42:34
Play later
Play later
Lists
Like
Liked
42:34
In this week's episode, we chat with Christian Angermayer. Christian co-founded atai Life Sciences and was an early investor in Compass Pathways -- two of the first companies commercializing psychedelic medicine. Christian also launched a fund dedicated to mental and neurological health called re:Mind, is an investor through his family office Apeir…
…
continue reading
1
Soltara: an ethical and profitable ayahuasca retreat
54:34
54:34
Play later
Play later
Lists
Like
Liked
54:34
In this week’s episode, we chat with Melissa Stangl, co-founder of Soltara Healing Center. Soltara is an ayahuasca retreat center whose ceremonies are lead by Shipibo healers, with locations in Peru and Costa Rica. The Shipibo people are from the Peruvian Amazon and are part of a tradition that has been drinking Ayahuasca for healing and spiritual …
…
continue reading
1
Microdosing (part 3): The path to FDA approval w/ MindMed and Diamond Therapeutics
58:24
58:24
Play later
Play later
Lists
Like
Liked
58:24
This is final episode in our 3-part series on microdosing that explores the science, history, and clinical applications. In this episode, we discuss the path to FDA approval for microdosing. We chat with the chief medical officers from Diamond Therapeutics and MindMed about their microdosing clinical programs. Diamond's program uses synthetic psilo…
…
continue reading
1
Microdosing (part 2): Placebo is a hell of a drug with Balázs Szigeti
37:28
37:28
Play later
Play later
Lists
Like
Liked
37:28
This is part 2 or our 3 part series on microdosing that explore the science, history, and clinical applications. In part 1, we interviewed psychedelic researcher James Fadiman about the fundamentals of microdosing. In part 2, we wanted to understand the placebo effect. In particular, is it the microdose that makes people feel better or it is a plac…
…
continue reading
1
Microdosing (part 1): James Fadiman and the fundamentals of microdosing
33:06
33:06
Play later
Play later
Lists
Like
Liked
33:06
In this 3-part series on microdosing, we explore the science, history, and its clinical potential. The anecdotal benefits of microdosing include better mood, creativity, and increased focus. But there are still many unanswered questions that remain. What is an effective dosing protocol? Is it safe in long term use? Does it even work or is it a plac…
…
continue reading
1
How the DEA and FDA will regulate psychedelic medicine
48:51
48:51
Play later
Play later
Lists
Like
Liked
48:51
In this week’s episode, we chat with Matt Zorn, an attorney at Yetter Coleman with expertise in DEA law, especially regarding psychedelics. Matt is currently challenging the DEA’s decision to schedule 5 new tryptamines, he recently argued Kathryn Tucker’s psilocybin “Right To Try” case against the DEA, and previously co-led Sue Sisley’s DEA case re…
…
continue reading
1
The state of psychedelics: Dr. Rachel Yehuda and Zach Haigney (live recording at Soho House)
45:45
45:45
Play later
Play later
Lists
Like
Liked
45:45
In this week’s special episode, Matias chats with Dr. Rachel Yehuda and Zach Haigney at Soho House in New York City. The episode was recorded in front of a live audience. Dr. Yehuda has spent the last 30 years doing research on PTSD and trauma and is leading the MDMA-assisted therapy research at the US Veterans Affairs Medical Center. She is the Di…
…
continue reading
1
Empowering the next wave of psychedelic therapists: Journey Clinical
41:41
41:41
Play later
Play later
Lists
Like
Liked
41:41
In Episode 18, we chat with Jonathan Sabbagh and Myriam Barthes, the co-founders of Journey Clinical, a platform that enables licensed therapists to offer ketamine-assisted psychotherapy (KAP). Journey Clinical provides licensed therapists with an on-demand KAP-trained medical team, customized treatments for each client, and a portal to connect wit…
…
continue reading
1
Osmind and the future of electronic health records in psychedelic medicine
36:19
36:19
Play later
Play later
Lists
Like
Liked
36:19
In today’s episode, we chat with Lucia Huang, the CEO and co-founder of Osmind, an electronic health record software system for treatment resistant mental health practices that is already in over 300 clinics. In this episode, we discuss: How Osmind makes data-driven decisions Osmind’s quick growth in only 2 years What it will take for insurance to …
…
continue reading
1
Palo Santo on investing in 2nd gen psychedelics and public markets
48:20
48:20
Play later
Play later
Lists
Like
Liked
48:20
In today’s episode, we chat with Tim Schlidt, a partner at Palo Santo. Palo Santo is a fund investing in psychedelic therapeutics. Palo Santo’s portfolio includes companies like Eleusis, Tactogen, and Journey Clinical. In this episode, we discuss: Tim’s background in healthcare finance Investing in classic psychedelic compounds vs. 2nd generation c…
…
continue reading
1
Designing psychedelic mindstates, with Mindstate Design Labs
56:42
56:42
Play later
Play later
Lists
Like
Liked
56:42
Today’s episode features Dillan Dinardo and Tom Ray, the co-founders of Mindstate Design Labs. Mindstate has a unique framework to design psychedelic compounds using what they call the “primer probe method.” This method involves combining a known psychedelic with a non-psychedelic compound. Mindstate just raised an $11.5M seed round. In this episod…
…
continue reading
1
MAPS PBC, rethinking the pharma business model and MDMA-assisted therapy
51:44
51:44
Play later
Play later
Lists
Like
Liked
51:44
Today’s episode features Amy Emerson, the CEO of MAPS Public Benefit Corporation (PBC), which is a fully owned subsidiary of MAPS, and its purpose is to commercialize MDMA-assisted therapy. We discuss the MAPS PBC and it’s business model for MDMA-assisted therapy. In this episode, we discuss: MAPS’ protocol and strategy behind FDA clinical trial fo…
…
continue reading
1
On transformational ketamine therapy and running an integrative psychedelic clinic
1:03:37
1:03:37
Play later
Play later
Lists
Like
Liked
1:03:37
In today’s episode, we discuss what it’s like being a psychologist who owns a psychedelic clinic. Genesee Herzberg is the co-founder of Sage Integrative Health, an integrative clinic in Berkeley, CA that offers ketamine-assisted therapy (KAP), psychotherapy, somatic therapy, and acupuncture. Genesee discusses her holistic approach to healing, and s…
…
continue reading
In today’s episode, we explore the therapeutic application of DMT across a range of diseases and conditions including Alzheimer’s, stroke, and organ transplants. While much of the attention in psychedelic medicine has been on their ability to address neuropsychiatric indications, research suggests that psychedelics like DMT have a far wider therape…
…
continue reading
1
Scaling Psilocybin Therapy: Compass Pathways' Lars Wilde
59:59
59:59
Play later
Play later
Lists
Like
Liked
59:59
Episode 10 features Lars Wilde, co-founder and Chief Business Officer of Compass Pathways, a mental health company with an initial focus on psilocybin therapy for Treatment-Resistant Depression. In this episode, we discuss: Lars’ experience overcoming Treatment-Resistant Depression with psilocybin The nuances of clinical trials and psilocybin dosin…
…
continue reading
Today's episode features three experts, Josh Hardman, Michael Haichin, and Graham Pechenik as they analyze atai’s S-1 in advance of their IPO. In this episode, we discuss: How atai went from idea to IPO in 3 years An overview of atai’s drug development programs and enabling technologies The platform’s strategy and risks Links to topics in this epis…
…
continue reading
1
A 30 year journey towards ibogaine approval: Deborah Mash, CEO of DemeRx
44:49
44:49
Play later
Play later
Lists
Like
Liked
44:49
Today's episode features Deborah Mash, founder and CEO of DemeRx, a clinical stage company developing ibogaine therapies to treat substance use disorders. In this episode, we discuss: The science, experience and the safety behind Ibogaine’s “neurochemical reset” Navigating US drug regulatory system and securing Intellectual Property Deborah’s 30 jo…
…
continue reading
1
Clinical trials, media, reciprocity, open science: Founder of The Trip Report, Zach Haigney
21:34
21:34
Play later
Play later
Lists
Like
Liked
21:34
Today's episode features Zach Haigney, creator of The Trip Report, a newsletter about psychedelics, policy and business. In 2019, Zach started writing The Trip Report and quickly grew his readership by analyzing psychedelic news headlines from every angle. He’s able to break through all the noise and report with a sense of fairness. In this episode…
…
continue reading
1
How to (legally) make psychedelic medicine: CEO of Psygen, Danny Motyka
30:53
30:53
Play later
Play later
Lists
Like
Liked
30:53
Today's episode features Danny Motyka, founder of Psygen, a Canadian manufacturer of psychedelics, like MDMA, LSD, DMT, and synthetic psilocybin. Psygen makes pharmaceutical grade psychedelic medicines for clinical research and therapeutic applications. They have a license to be one of the first manufacturing facilities dedicated to the synthesis o…
…
continue reading
1
From serving medicine to company founder: NANA founder Flor Bollini
33:10
33:10
Play later
Play later
Lists
Like
Liked
33:10
Today's episode features Flor Bollini, founder of NANA, an online platform that guides patients on using psychedelic medicine for holistic healing. NANA provides personalized protocols based on an assessment of your mental, emotional and physical health. From there you are partnered with a Nana or guide who leads telemedicine therapy that incorpora…
…
continue reading
1
Helping psychedelic practitioners through software: Maya Health CEO David Champion
29:29
29:29
Play later
Play later
Lists
Like
Liked
29:29
Today's episode features David Champion, CEO and co-founder of Maya, a software platform that helps practitioners and clinics manage psychedelic-assisted therapy practices. The data collected from treatments will help psychedelic stakeholders, from researchers to pharmaceutical companies, discover insights for safer and more effective treatments. I…
…
continue reading
1
How to invest in psychedelic companies: Vine Ventures' Founder Ryan Zurrer
57:10
57:10
Play later
Play later
Lists
Like
Liked
57:10
Today's episode features Ryan Zurrer, founder of Vine Ventures, one of the first venture capital funds investing in psychedelic medicine. Ryan has deep roots in psychedelics culture and understands the many cultures within the psychedelic space. His fund is aligned with those values. If you’re a founder, investor, or early hire at a psychedelic com…
…
continue reading
1
Building a psychedelic media company: DoubleBlind's Shelby Hartman and Madison Margolin
26:37
26:37
Play later
Play later
Lists
Like
Liked
26:37
Today’s episode features Shelby Hartman and Madison Margolin from DoubleBlind, a psychedelic magazine and media company founded in 2019 covering timely, untold stories about the expansion of psychedelics around the globe. Focused on how the industry can engage in sacred reciprocity and ethical psychedelic therapies, DoubleBlind is a for-profit comp…
…
continue reading
1
Dylan Beynon, CEO of Mindbloom: How ketamine-assisted therapy treats anxiety and depression
31:19
31:19
Play later
Play later
Lists
Like
Liked
31:19
Today’s episode features Dylan Beynon from Mindbloom, a mental and wellbeing startup that is currently offering ketamine-assisted therapy to treat anxiety and depression. Mindbloom is opening clinics across the country and is using technology to lower the cost of treatment. Host Greg Kubin participates in a ketamine-assisted therapy session in the …
…
continue reading